Financial Performance - Total revenue for the first quarter reached ¥651,435,637.54, an increase of 31.82% compared to ¥494,167,309.59 in the same period last year[8]. - Net profit attributable to shareholders was ¥89,201,436.67, up 22.99% from ¥72,528,210.28 year-over-year[8]. - Net profit excluding non-recurring gains and losses was ¥81,900,915.14, reflecting a 27.35% increase from ¥64,310,267.42 in the previous year[8]. - Basic earnings per share increased to ¥0.21, a rise of 16.67% compared to ¥0.18 in the same period last year[8]. - The operating profit was CNY 104,255,686.19, reflecting a growth of 28.64% year-on-year[29]. - The company achieved total operating revenue of CNY 651,435,637.54, an increase of 31.82% compared to the same period last year[29]. - Net profit for the current period was ¥92,274,118.33, compared to ¥75,536,394.76 in the previous period, indicating a growth of 22.1%[94]. - Basic and diluted earnings per share were both ¥0.21, an increase from ¥0.18 in the previous period[97]. Cash Flow and Financial Position - The net cash flow from operating activities was negative at ¥82,449,829.13, a significant decline of 530.77% from a negative ¥13,071,386.44 in the previous year[8]. - Cash flow from operating activities increased by 28.51%, driven by higher sales revenue[26]. - The company reported a significant decrease in the sales price of hepatitis B immunoglobulin, which has affected expected profit margins from this product line[58]. - The total cash inflow from operating activities was ¥597,297,232.82, compared to ¥464,789,489.80 in the previous period, indicating a growth of 28.5%[104]. - The cash outflow from operating activities totaled ¥679,747,061.95, up from ¥477,860,876.24, resulting in a net cash flow from operating activities of -¥82,449,829.13[104]. - The ending balance of cash and cash equivalents was ¥730,279,632.80, down from ¥395,357,977.52 in the previous period[110]. - The company’s cash flow management appears to be under pressure, as indicated by the significant drop in cash and cash equivalents[71]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,024,152,316.94, a decrease of 0.97% from ¥5,073,150,178.05 at the end of the previous year[8]. - Current assets decreased to CNY 2,995,752,914.37 from CNY 3,046,890,484.83, a decline of approximately 1.7%[71]. - Total liabilities remained relatively stable at CNY 1,304,718,897.35 compared to CNY 1,302,614,874.58, showing a slight increase of 0.2%[79]. - Short-term borrowings increased significantly to CNY 193,350,000.00 from CNY 95,000,000.00, marking an increase of approximately 103.5%[74]. - Total equity attributable to shareholders decreased to CNY 3,650,485,050.82 from CNY 3,704,659,616.36, a decline of approximately 1.5%[80]. Research and Development - The company experienced a 51.96% increase in R&D expenses, indicating a focus on innovation and development[26]. - The company reported a significant increase in research and development expenses, which rose to ¥11,773,964.79 from ¥7,748,198.38, highlighting a focus on innovation[91]. Shareholder Information - The company had a total of 14,011 common shareholders at the end of the reporting period[14]. - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., held 30.95% of the shares, totaling 134,121,412 shares[14]. Investment and Projects - The single plasma station construction and renovation project has an investment progress of 99.85% with a total investment of 280.12 million CNY[54]. - The hepatitis B immunoglobulin series industrialization project has an investment progress of 89.73% with a total investment of 234.74 million CNY[54]. - The company plans to invest 1,000 million RMB to establish the Beijing R&D center, which aims to enhance its capabilities in developing specific immunoglobulin products and other blood products[56]. - The acquisition of a 32% stake in Zhejiang Haikang Biological Products Co., Ltd. was completed with an investment of 3,594.45 million RMB, marking a strategic move to strengthen the company's market position[56]. Regulatory and Compliance - The company has committed to avoid any potential competition with its controlling shareholder by designating itself as the sole platform for blood product business integration[40]. - The company has established a plan to resolve competition issues with Danxia Biopharmaceuticals, ensuring compliance with regulatory requirements[41]. - The company has not reported any significant changes in its intangible assets or core competencies during the reporting period[31]. - The company has not identified any major risk factors or operational difficulties affecting its future operations[35]. - The first quarter report has not been audited, which may affect the reliability of the financial data presented[119].

Financial Performance - Operating revenue for the current period reached CNY 594,329,442.80, a 98.59% increase year-on-year[7] - Net profit attributable to shareholders was CNY 95,401,739.03, up 44.94% compared to the same period last year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 96,943,321.15, a 39.33% increase year-on-year[7] - Basic earnings per share increased by 37.50% to CNY 0.22[7] - Operating revenue for the first nine months of 2018 reached ¥1.69 billion, a 100.86% increase from ¥839.71 million in the same period of 2017, driven by sales growth and the consolidation of Fuda Pharmaceutical[15] - Total revenue for the third quarter reached ¥594,329,442.80, a significant increase of 99% compared to ¥299,270,269.57 in the same period last year[41] - Operating profit for the quarter was ¥119,276,402.25, up from ¥84,307,235.79, reflecting a growth of approximately 41.5%[42] - Net profit attributable to the parent company was ¥95,401,739.03, compared to ¥65,821,410.03 in the previous year, marking an increase of about 45%[42] - The company's total revenue for the year-to-date reached ¥1,686,615,645.26, a significant increase from ¥839,705,689.20 in the previous year, representing a growth of about 100.5%[46] - The net profit attributable to the parent company for the current period was ¥286,364,968.99, compared to ¥223,556,236.08 in the previous period, reflecting an increase of approximately 28%[48] Asset and Liability Changes - Total assets increased by 41.50% to CNY 5,192,537,478.46 compared to the end of the previous year[7] - Net assets attributable to shareholders increased by 46.87% to CNY 3,562,779,906.50 compared to the end of the previous year[7] - As of September 30, 2018, the total assets of the company amounted to ¥5,192,537,478.46, an increase from ¥3,669,635,080.76 at the beginning of the period[34] - Total liabilities increased to ¥1,562,885,290.68 from ¥1,185,331,195.22, marking an increase of about 32%[35] - The company's equity attributable to shareholders rose to ¥3,562,779,906.50 from ¥2,425,746,385.35, reflecting an increase of approximately 47%[35] - Current assets totaled ¥2,613,791,676.51, up from ¥1,082,155,764.87, indicating a growth of around 142.4%[38] - Total liabilities increased to ¥1,088,042,248.56 from ¥512,943,526.50, reflecting a growth of about 112%[38] - The company's equity increased to ¥3,570,274,764.40 from ¥2,378,934,929.38, a rise of approximately 50%[39] Cash Flow and Investments - Cash flow from operating activities for the year-to-date reached CNY 66,080,655.82, a significant increase of 169.43%[7] - Cash inflows from operating activities amounted to CNY 1.58 billion, significantly up from CNY 795.46 million year-over-year, indicating a growth of approximately 99%[53] - The net cash flow from operating activities was CNY 66.08 million, a recovery from a net outflow of CNY 95.18 million in the previous year[55] - The company reported a net cash outflow from investing activities of CNY 1.05 billion, compared to a net outflow of CNY 157.62 million in the same period last year, reflecting increased investment activities[55] - Cash flow from financing activities generated a net inflow of CNY 1.21 billion, up from CNY 234.09 million in the previous year, indicating strong financing efforts[55] - The ending cash and cash equivalents balance was CNY 722.09 million, an increase from CNY 401.30 million at the end of the previous year, showing a growth of approximately 80%[56] - The company raised CNY 1.01 billion from investments, with CNY 425 million coming from loans, indicating robust capital acquisition strategies[59] Shareholder and Ownership Information - The company reported a total of 14,641 common shareholders at the end of the reporting period[11] - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., holds 30.95% of the shares[11] - The chairman of the company has increased his shareholding by acquiring 511,200 shares at an average price of ¥30.78 per share[19] - The company has a commitment to not transfer shares for 36 months post-IPO, ensuring stability in shareholding[24] - The company’s controlling shareholder has committed to avoid any business competition with the issuer and will prioritize the issuer for any overlapping business acquisitions[22] - The company has committed to avoiding any competition with its own business during its shareholding period[25] Research and Development - The company has entered into a collaboration with Wytold Richard Lebing for the innovation and development of blood products, marking a unique partnership in the domestic industry[18] - Research and development expenses increased to ¥5,280,998.63 from ¥3,302,084.64, marking a rise of about 60%[44] Compliance and Transparency - The company has disclosed important matters through its official reporting channels, ensuring transparency[20] - The company has committed to minimizing related party transactions and ensuring compliance with legal and regulatory requirements[24] - The company reported no violations of external guarantees during the reporting period[28] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[29] - The report was not audited, which may affect the perception of the financial data's reliability[60]

Supply Chain and Raw Materials - The company reported a significant risk regarding the supply of raw materials, specifically healthy human plasma, which is currently in tight supply due to regulatory constraints [5]. - The company faces a risk of insufficient raw material supply for blood products due to tight supply of healthy human plasma, which directly affects production scale [87]. - The company plans to increase the number of plasma collection stations by applying for new ones and exploring existing stations' potential to ensure a steady supply of plasma [88]. Product Development and Quality Control - The development cycle for new blood products is lengthy, and delays in obtaining product registration certificates could adversely affect the launch of new products [8]. - The company emphasizes the importance of product quality control, as any quality issues could lead to production halts and reputational damage [9]. - The company has established a comprehensive quality management system to mitigate product quality control risks, which are critical for maintaining brand reputation and market position [89]. - The company is actively developing new blood products, including coagulation factors and immunoglobulin projects, with several products in clinical trial stages [46][47]. Financial Performance - Total revenue for the reporting period reached ¥1,092,286,202.46, representing a 102.11% increase compared to ¥540,435,419.63 in the same period last year [26]. - Net profit attributable to shareholders was ¥190,963,229.96, up 21.07% from ¥157,734,826.05 year-on-year [26]. - The net cash flow from operating activities improved significantly to ¥73,949,241.34, compared to a negative cash flow of ¥64,432,241.91 in the same period last year, marking a 214.77% increase [26]. - Basic earnings per share increased to ¥0.46, a rise of 17.95% from ¥0.39 [26]. Investments and Acquisitions - The company invested in and acquired a 75% stake in Fuda Pharmaceutical, a key blood product distributor in Guangdong Province [37]. - The company completed the acquisition of minority interests in several plasma stations for a total of 60 million yuan, resulting in 100% ownership of these stations [140]. - The company has a total commitment of CNY 165,133.69 million for investment projects, with CNY 154,774.99 million already invested [72]. Market Position and Competition - The pharmaceutical industry is experiencing rapid growth, but the company acknowledges the increasing competition and potential risks associated with future investment projects [10]. - The company aims to become a "world-class blood product enterprise" and a benchmark in the pharmaceutical industry, focusing on expanding its product lines in diabetes and related complications [37]. - The company is focused on external expansion in the pharmaceutical industry, which is supported by national policies and growing market demand, but it acknowledges the increasing competition and potential risks in investment projects [89]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment [12]. - The company holds 18.68% of its shares as restricted shares, which increased to 24.73% after the recent share issuance [144]. - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., holds 30.95% of the shares [150]. Research and Development - The company has established a strong R&D capability, continuously optimizing its product structure in immunoglobulin and factor products [39]. - The company is actively developing non-blood products alongside its core blood product business to achieve synergistic growth [34]. - The company has decided to terminate the blood product R&D center project due to the establishment of a new R&D center in Beijing, which offers regional and talent advantages [75]. Environmental Compliance - The company and its subsidiaries are listed as key pollutant discharge units by environmental protection authorities, indicating compliance with environmental regulations [122]. - The total COD emissions from Boya Bio amounted to 1106.5 kg, which is below the regulatory limit of 7050 kg [123]. - All companies have established emergency response plans for environmental incidents, enhancing their ability to manage public crises and protect the environment [132]. Risk Management - The company has a risk of goodwill impairment due to the acquisition of Tianan Pharmaceutical, Xinbai Pharmaceutical, and Fuda Pharmaceutical, which could negatively impact its financial results if their performance deteriorates [89]. - The company will conduct thorough research and due diligence on investment targets to minimize project investment risks [89]. - The company is at risk of not obtaining product registration certificates for new products, which could delay their launch; it aims to leverage its advantages in specific immunoglobulin products to enhance R&D efforts [88].

Financial Performance - The company's operating revenue for 2017 was ¥1,460,521,856.51, representing a 54.29% increase compared to ¥946,596,099.59 in 2016[19]. - The net profit attributable to shareholders for 2017 was ¥356,588,468.22, a 31.08% increase from ¥272,041,808.98 in 2016[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥337,284,755.83, up 25.66% from ¥268,417,433.76 in 2016[19]. - The company's total assets at the end of 2017 were ¥3,669,635,080.76, a 51.67% increase from ¥2,419,482,434.17 at the end of 2016[19]. - The total equity attributable to shareholders at the end of 2017 was ¥2,425,746,385.35, reflecting a 15.88% increase from ¥2,093,396,641.90 at the end of 2016[19]. - The company reported a negative net cash flow from operating activities of ¥23,816,154.13 in 2017, a decline of 111.98% compared to a positive cash flow of ¥198,756,138.54 in 2016[19]. - The basic earnings per share for 2017 was ¥0.89, down 12.75% from ¥1.02 in 2016[19]. - The diluted earnings per share for 2017 was also ¥0.89, reflecting the same percentage decrease as the basic earnings per share[20]. Dividend Distribution - The company reported a cash dividend of RMB 1.50 per 10 shares, totaling RMB 64,998,729.45, based on a total share capital of 433,324,863 shares as of the day before the report disclosure[5]. - The cash dividend for 2017 represents 18.23% of the net profit attributable to ordinary shareholders, which is 356,588,468.22 yuan[131]. Acquisitions and Investments - The company acquired 82% of Guangdong Fuda Pharmaceutical Co., Ltd. for ¥218.12 million, which generated revenue of ¥510,805,052.77 and a net profit of ¥28,373,493.69 in 2017[49]. - The company invested in acquiring an 82% stake in Fuda Pharmaceutical, a key blood product distributor in Guangdong, which is the largest blood product market in China[31]. - The company acquired 99% of Danxia Biopharmaceutical Co., Ltd. on April 1, 2017, to address potential competition in the blood products sector[133]. - The company plans to increase its stake in Fuda Pharmaceutical to 75% through an additional investment of ¥35.40 million[74]. Product Development and R&D - The company specializes in the research, production, and sales of blood products, including three main categories: albumin, immunoglobulin, and coagulation factors, with a total of 21 specifications[30]. - The company is committed to continuous innovation and optimization in its production processes to enhance product yield and efficiency[34]. - The company has invested in R&D for specific immunoglobulins and coagulation factor products to expand its product offerings[120]. - The company has initiated research on the bioactive substance detection methods for the compound bone peptide series products and upgraded standards for oxytocin series products[57]. Market and Industry Risks - The company faces a significant risk of raw material supply shortages due to the tight supply of healthy human plasma, which directly impacts production capacity[3]. - The company has a risk of product registration delays, which could affect the launch of new blood products, as the approval process involves multiple lengthy stages[4]. - The company faces risks related to raw material supply, as the availability of healthy human plasma is critical for production and is currently in tight supply[118]. Marketing and Sales - The company has enhanced its marketing capabilities by expanding its marketing network and investing in marketing efforts[33]. - The company plans to enhance its blood products business by applying for new plasma collection stations and increasing marketing efforts to improve public awareness[117]. - The blood products business generated revenue of ¥742,452,940.09, up 40.43%, accounting for 50.83% of total revenue[48]. Financial Management and Cash Flow - Operating cash inflow totaled ¥1,100,723,638.26, a 38.00% increase year-on-year, attributed to sales revenue growth[82]. - Operating cash outflow increased by 87.78% to ¥1,124,539,792.39, mainly due to raw material purchases[83]. - Investment cash inflow rose by 221.37% to ¥329,307,246.46, mainly from the maturity of financial products and the sale of a 37% stake in a subsidiary[85]. - Financing cash inflow surged by 1,776.66% to ¥586,234,891.32, primarily due to bank loans[87]. Corporate Governance and Compliance - The company has made commitments to avoid related party transactions and ensure compliance with legal regulations[136]. - The company has established measures to prevent any form of competition with Boya Biopharmaceutical during the shareholder's tenure[136]. - The controlling shareholder committed to bear any liabilities related to social security and housing fund contributions for employees[134]. Environmental Responsibility - The company has a wastewater treatment system with a daily capacity of 500 cubic meters, achieving an average COD concentration of 54.22 mg/L[183]. - The company processed approximately 77,000 tons of wastewater in 2017, meeting the first-level discharge standards[183]. - The company has not experienced any major environmental pollution incidents and complies with national environmental standards[185]. Social Responsibility - The company actively participates in social responsibility initiatives, including poverty alleviation efforts in local villages[176]. - The company invested CNY 23.5 million in five poverty alleviation projects focused on agricultural and forestry industries[178]. - The company provided CNY 1 million in funding to support one impoverished student[179].

博雅生物制药集团股份有限公司 2018 年第一季度报告全文 博雅生物制药集团股份有限公司 2018 年第一季度报告 2018-038 2018 年 04 月 1 博雅生物制药集团股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人廖昕晰、主管会计工作负责人范一沁及会计机构负责人(会计主 管人员)魏源新声明：保证季度报告中财务报表的真实、准确、完整。 2 博雅生物制药集团股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据：□ 是 √ 否 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业总收入（元） | 494,167,309.59 | 222,979,579.09 | | 121.62% | | 归属于上市公司股东的 ...

Financial Performance - Net profit attributable to shareholders decreased by 11.03% to ¥65,821,410.03 for the reporting period[8] - Operating revenue for the period reached ¥299,270,269.57, reflecting an 18.68% increase year-on-year[8] - Basic earnings per share fell by 42.86% to ¥0.16, while diluted earnings per share also decreased by 42.86% to ¥0.16[8] - The company reported a year-to-date net profit of ¥223,556,236.08, which is a 24.42% increase compared to the same period last year[8] - The company reported a significant increase in sales expenses, which rose to CNY 83,591,142.94 from CNY 24,890,876.08, an increase of 235%[47] - The total comprehensive income for the period was ¥186,796,441.27, compared to ¥130,734,832.60 in the previous period, representing an increase of approximately 42.9%[58] Assets and Liabilities - Total assets increased to ¥2,971,883,472.65, a rise of 22.83% compared to the previous year[8] - Accounts receivable increased by 76.03% to CNY 193,163,359.70, primarily due to increased sales revenue[19] - Inventory rose by 46.93% to CNY 424,213,463.02, attributed to higher collection of raw plasma and increased blood product inventory[19] - Total liabilities increased significantly, with long-term borrowings rising by 1,219.24% to CNY 292,145,000.00, reflecting new bank loans[19] - The total current assets reached CNY 1,390,640,372.51, up from CNY 1,010,681,599.86, reflecting improved liquidity[38] - Non-current assets totaled CNY 1,581,243,100.14, compared to CNY 1,408,800,834.31 at the start of the period, indicating investment in long-term growth[39] Cash Flow - Net cash flow from operating activities showed a significant decline of 214.64%, totaling -¥95,180,333.29[8] - The company reported a net cash flow from operating activities of -95,180,333.29, a decrease of 214.64% compared to the same period last year[20] - The company received other cash related to operating activities amounting to 40,914,076.54, an increase of 180.95% year-on-year, mainly due to increased interest income and government subsidies[20] - The company reported a significant increase in financing activities, with net cash flow of 234,090,625.24, compared to -76,795,379.86 in the previous year[20] - Cash inflows from financing activities were ¥350,927,014.31, significantly higher than ¥30,930,397.57 in the previous period[62] - The net cash flow from financing activities was positive at ¥234,090,625.24, compared to a negative -¥76,795,379.86 in the prior period[62] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,854[13] - The largest shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., held 33.44% of shares, totaling 134,121,412 shares[13] Investments and Future Plans - The company plans to acquire 82% of Guangdong Fuda Pharmaceutical Co., Ltd. to expand its marketing channels and strengthen its product promotion[21] - The company intends to issue no more than 37.5 million shares to raise up to 1 billion yuan for the construction of a large-scale blood product intelligent factory[21] - The company plans to purchase up to 100 tons of raw plasma and 180 tons of plasma components for the production of immunoglobulin, with a total budget not exceeding 402 million yuan[23] Other Financial Metrics - The weighted average return on net assets decreased by 0.85 percentage points to 2.92%[8] - Non-recurring gains and losses amounted to ¥18,237,378.25 for the year-to-date[11] - The company received government subsidies, leading to a 497.21% increase in other operating income to CNY 12,403,896.25[19] - The company’s tax payments rose by 79.57% to 123,074,556.17, attributed to increased revenue and tax settlements from the previous year[20] - The company reported a total comprehensive income of CNY 228,827,396.76 for the year-to-date, an increase of 24.8% from CNY 183,387,599.62 in the previous year[55] Audit and Compliance - The report was not audited, indicating that the figures may be subject to change upon final review[66] - The company reported no violations regarding external guarantees during the reporting period[33] - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[34] - The company has committed to avoiding any form of competition with its own business during the period of shareholding[30] - All parties involved have strictly adhered to their commitments during the reporting period[32]

Raw Material Supply and Production Challenges - The company reported a significant challenge in securing raw materials, specifically healthy human plasma, which is critical for blood product production, leading to a tight supply situation in the industry[4]. - The company anticipates a significant risk in raw material supply due to tight availability of human plasma, which directly impacts production capacity[91]. - The company plans to increase the number of plasma collection stations and is actively seeking acquisition targets to enhance plasma supply[91]. - The company is currently navigating risks associated with the lengthy process of obtaining product registration certificates from the National Medical Products Administration, which could delay new product launches[5]. - There is a risk associated with the approval of new products, which may delay market entry if registration certificates are not obtained in time[92]. Financial Performance - Total revenue for the reporting period reached ¥540,435,419.63, an increase of 34.55% compared to the same period last year[21]. - Net profit attributable to shareholders was ¥157,734,826.05, reflecting a growth of 49.23% year-over-year[21]. - Net profit after deducting non-recurring gains and losses was ¥135,741,728.60, up by 30.35% from the previous year[21]. - The net cash flow from operating activities was -¥64,432,241.91, a decline of 261.67% compared to the same period last year[21]. - Total assets at the end of the reporting period amounted to ¥2,906,129,925.32, representing a 20.11% increase from the end of the previous year[22]. - The net assets attributable to shareholders increased to ¥2,224,399,093.18, a rise of 6.26% year-over-year[22]. - The weighted average return on equity improved to 7.28%, an increase of 1.75 percentage points compared to the previous year[22]. Shareholder and Capital Management - The company plans to not distribute cash dividends or issue bonus shares, indicating a focus on reinvestment rather than shareholder payouts[6]. - No cash dividends or stock bonuses are planned for the half-year period, nor will there be a capital reserve transfer to increase share capital[96]. - The controlling shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., committed to not transferring or entrusting the management of shares for 60 months from the date of the company's stock listing[97]. - Shareholders including Jiangxi Xinxing Biotechnology Development Co., Ltd. and Shenzhen Ronghua Investment Co., Ltd. committed to not transferring or entrusting the management of shares for 36 months from the date of the company's stock listing[97]. - The company plans to issue up to 37.5 million shares to raise a maximum of ¥1 billion for the construction of a "thousand-ton level blood products intelligent factory"[53]. Research and Development - The company is actively working on new product development, but the timeline for obtaining necessary approvals remains uncertain[5]. - The company has a strong R&D capability, with a complete product line including albumin, immunoglobulin, and coagulation factors[38]. - The company achieved a 64.91% completion rate for the development of coagulation factor products, with CNY 2,990.69 million invested[80]. - The company has acquired 5 invention patents during the reporting period, enhancing its R&D capabilities[122]. Investment and Acquisitions - The company has completed the acquisition of 99% of Danxia Biotech, which specializes in blood product production and sales, although it is currently under regulatory scrutiny[56]. - The company has invested ¥50 million in a pharmaceutical industry merger fund, which has raised ¥3.615 billion to date, with ongoing fundraising efforts[55]. - The company has invested CNY 10,000 million in Boya Investment, achieving a 100% investment completion rate[78]. - The company has allocated CNY 24,261.37 million for working capital, achieving a 100% investment completion rate[78]. Corporate Governance and Compliance - The company’s board of directors and management have confirmed the accuracy and completeness of the financial report, taking legal responsibility for its contents[4]. - The half-year financial report for the company has not been audited[103]. - There are no significant litigation or arbitration matters reported during the period[104]. - The company has established commitments to avoid and reduce related party transactions, ensuring compliance with legal and regulatory requirements[100]. Social Responsibility and Community Engagement - The company donated RMB 3 million to the China Medical and Health Development Foundation for public welfare projects[120]. - The company has actively participated in social responsibility initiatives, contributing RMB 245,000 for poverty alleviation efforts[119].

江西博雅生物制药股份有限公司 2017 年第一季度报告 江西博雅生物制药股份有限公司 2017 年第一季度报告全文 2017-045 2017 年 04 月 1 江西博雅生物制药股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均出席了审议本次季报的董事会会议。 2 江西博雅生物制药股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 222,979,579.09 | 176,012,894.17 | 26.68% | | 归属于上市公司股东的净利润（元） | 67,455,910.46 | 38,540,021.29 | 75.03% | | 归属于上市公司股东的扣除 ...

Financial Performance - The company's operating revenue for 2016 was ¥946,596,099.59, representing a 74.27% increase compared to ¥543,182,670.87 in 2015[21]. - The net profit attributable to shareholders for 2016 was ¥272,041,808.98, a 79.21% increase from ¥151,798,745.01 in 2015[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥268,417,433.76, reflecting a 115.27% increase from ¥124,685,873.53 in 2015[21]. - The net cash flow from operating activities for 2016 was ¥198,756,138.54, up 35.19% from ¥147,018,107.73 in 2015[21]. - The total assets at the end of 2016 were ¥2,419,482,434.17, a 10.57% increase from ¥2,188,215,551.87 at the end of 2015[21]. - The net assets attributable to shareholders at the end of 2016 were ¥2,093,396,641.90, an 11.66% increase from ¥1,874,831,793.12 at the end of 2015[21]. - The basic and diluted earnings per share for 2016 were both ¥1.02, a 54.55% increase from ¥0.66 in 2015[21]. - The company achieved total operating revenue of ¥946,596,099.59, a year-on-year increase of 74.27%[49]. - The blood products business generated operating revenue of ¥528,688,011.14, up 54.43% year-on-year, accounting for 55.85% of total revenue[52]. - The net profit from the blood products segment was ¥191,802,718.06, reflecting a 49.34% increase year-on-year, contributing 70.50% to the net profit attributable to shareholders[52]. Investment and Capital Structure - The company plans to distribute cash dividends of RMB 1.00 per 10 shares, totaling RMB 26,738,480.10, based on a total share capital of 267,384,801 shares as of the end of 2016[9]. - The company will also increase its share capital by 5 shares for every 10 shares held, resulting in a total of 401,077,201 shares after the increase[9]. - The company has a total of CNY 92,292.63 million in raised funds, with CNY 79,940.47 million already utilized, leaving CNY 16,305.52 million unutilized[104]. - The company plans to establish a pharmaceutical industry merger and acquisition fund with a maximum investment of 150 million yuan, aiming to raise up to 600 million yuan for equity investments in unlisted companies[98]. - The company has committed to invest CNY 5,000 million in the coagulation factor product R&D building project, with CNY 2,892.68 million already invested, representing 57.85% of the planned investment[109]. Research and Development - The company has significantly increased its R&D expenditure, with development costs rising by 172.65% year-on-year due to investments in new product research[38]. - The company established an academic workstation and partnered with Fudan University to enhance R&D capabilities in chemical drugs[62]. - The company plans to conduct further research on the production processes of four new drug varieties, including hydroxyl phenyl sulfonate calcium[62]. - The company is actively preparing for production site inspections to obtain product approvals and GMP certification for new products[62]. - The company plans to enhance its marketing capabilities and optimize its marketing network to support revenue growth[54]. Market Position and Strategy - The company aims to become a world-class blood product enterprise and a respected pharmaceutical group, focusing on blood products while expanding into non-blood product sectors[37]. - The company is focused on consolidating its position in the blood products sector while also expanding into diabetes medications and other pharmaceutical areas[122]. - The company benefits from favorable policies that allow market-driven pricing for blood products, enhancing its profitability[123]. - The company is collaborating with LFB to develop vWF factor, with significant progress in technology transfer and process analysis[61]. - The company is advancing clinical trials for its coagulation factor VIII product, with patient enrollment currently ongoing[58]. Operational Challenges and Risks - The company acknowledges the risk of goodwill impairment if the operational performance of its subsidiaries deteriorates[9]. - The company faces risks related to raw material supply shortages, particularly in plasma collection, and plans to secure supply by maximizing existing station potential and applying for new stations[133]. - The company is one of the few with the qualification to apply for new plasma collection stations, but faces high uncertainty due to varying national policies and regional environments[6]. - The pharmaceutical industry, which the company primarily invests in, is supported by national policies and has a high market demand, but competition is intensifying[9]. Corporate Governance and Compliance - The company’s financial report has been confirmed as true, accurate, and complete by its board of directors and management[3]. - The company has no significant litigation or arbitration matters during the reporting period[164]. - The company has not engaged in any major related party transactions during the reporting period[168]. - The company has not reported any non-operating related party debts during the reporting period[171]. - The company has maintained a commitment to avoid competition with its controlling shareholder, ensuring business integrity[151]. Social Responsibility - The company actively participated in social responsibility initiatives, including donations to education for impoverished families totaling CNY 40,000[184]. - The company provided financial assistance of CNY 266,600 to Guangchang Dongying Village and CNY 404,000 to Dongxiang County Dongyuan Village as part of its poverty alleviation efforts[184].

Financial Performance - Net profit attributable to shareholders rose by 119.80% to CNY 73,980,659.92 for the reporting period[7] - Operating revenue for the period reached CNY 252,159,651.98, reflecting a growth of 90.00% year-on-year[7] - Basic earnings per share increased by 86.67% to CNY 0.28[7] - In the first three quarters of 2016, the company's total operating revenue reached CNY 653.83 million, a year-on-year increase of 82.69%[20] - The blood products business generated CNY 354.14 million in revenue, accounting for 54.16% of total revenue, with a year-on-year growth of 52.60%[23] - The diabetes drug segment, Tianan Pharmaceutical, achieved revenue of CNY 138.83 million, reflecting an 11.74% increase year-on-year[24] - The biochemical drug segment, Xinbai Pharmaceutical, contributed CNY 160.86 million in revenue since its consolidation, enhancing overall operational quality[25] - Total operating revenue for the third quarter reached CNY 252,159,651.98, a significant increase of 89.9% compared to CNY 132,715,357.90 in the same period last year[68] - Net profit attributable to the parent company was CNY 73,980,659.92, up 120% from CNY 33,657,452.97 year-over-year[69] - The company's total equity attributable to shareholders rose to CNY 2,043,298,270.56, compared to CNY 1,966,009,810.44 at the beginning of the period, an increase of 3.9%[66] Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY 83,022,935.04, a decrease of 1.16% compared to the previous year[7] - The company's cash and cash equivalents decreased by 31.05% compared to the beginning of the period, primarily due to repayment of short-term loans[20] - The company's cash and cash equivalents decreased from approximately 698.44 million yuan to 481.58 million yuan, reflecting a reduction of about 30.9%[60] - The company's inventory increased from approximately 214.38 million yuan to 270.86 million yuan, representing a growth of about 26.3%[60] - The total liabilities decreased from approximately 280.11 million yuan to 237.42 million yuan, a reduction of about 15.2%[62] - The company's retained earnings increased from approximately 366.38 million yuan to 492.62 million yuan, showing a growth of about 34.4%[62] - The company's cash flow from financing activities included cash received from borrowings of ¥30,000,000.00, down from ¥67,145,000.00 in the previous period, indicating a decrease of about 55.4%[87] Investment and Acquisitions - The company is actively pursuing investments and acquisitions in the pharmaceutical industry, which is experiencing intense competition[12] - There is a risk of goodwill impairment due to the acquisition of Tianan Pharmaceutical and Xinbai Pharmaceutical, which could negatively affect the company's financial performance[13] - The company acknowledges investment risks in the pharmaceutical industry and plans to conduct thorough research and due diligence on potential investment targets[34] - The company has committed to avoiding competition with its controlling shareholder and ensuring that its blood product business remains the sole integration platform[39] - The total amount of raised funds is ¥92,292.63 million, with ¥215.02 million invested in the current quarter[48] - Cumulative investment of raised funds reached ¥77,115.82 million, with no changes in the use of raised funds reported[48] - The company plans to use up to 150 million yuan of its own funds to establish a pharmaceutical industry merger fund with its controlling shareholder, aiming to raise a total of 600 million yuan for investments in third-party medical testing services and other projects[54] Research and Development - The company aims to strengthen its blood product business while enhancing revenue and profitability in non-blood product sectors[30] - The company is focusing on accelerating the research and development of coagulation factor products to ensure sustainable growth[33] - The company reported a total of ¥1,933.12 million invested in the development of coagulation factor products, with a progress of 38.66%[48] - The company decided to terminate the blood product R&D center project due to the establishment of a new R&D center in Beijing, which offers better regional and talent advantages[50] - The company plans to use 46.08 million yuan of its remaining raised funds for the construction of a research and development building for coagulation factor products[54] Risks and Challenges - The company faces high uncertainty in applying for new plasma stations due to varying national policies and regional environments[10] - Risks associated with new product registrations could delay the launch of new products, impacting future revenue[11] - There is a risk of goodwill impairment due to the acquisition of Tianan Pharmaceutical and Xinbai Pharmaceutical, which the company plans to manage through effective subsidiary oversight[35]